Millions of Ohioans don't know they're inhaling air poisoned by radon, a gas estimated to lurk beneath about 50% of Ohio ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

Dr. Charles M. Rudin highlighted new small cell lung cancer therapies, including T cell engagers, antibody-drug conjugates, ...

Kelun Biotech's sac-TMT plus Merck's Keytruda shows significant progress in late-stage lung cancer trial. Read more here.

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology ...

Given that many tiny nodules were found, these are unlikely to be lung cancer, which is generally only a single nodule ...

The FDA has granted full approval to tarlatamab-dlle (Imdelltra) for the treatment of adult patients with extensive stage ...

Explore how DeepTarget can change perspectives on drug repurposing by broadening the view of small molecule targets.

A new randomized trial from North Carolina suggests that digital tools like mPATH may slightly boost participation in CT lung ...

Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.

Gilead has reported that its phase 3 ASCENT-07 trial evaluating Trodelvy (sacituzumab govitecan-hziy) as a first-line ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...